Leerink Partners analyst Jonathan Chang maintained a Buy rating on Xencor (NASDAQ:XNCR) Inc on Wednesday, setting a price target of $42, which is approximately 31.95% above the present share price of $31.83.
Chang expects Xencor Inc to post earnings per share (EPS) of -$0.14 for the third quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Xencor, with an average price target of $42.67.
The analysts price targets range from a high of $52 to a low of $21.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $32.39 million and a net profit of -$8.78 million. The company's market cap is $1.76 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 29.0% and a 50.00% success rate.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.